Ma Ning, Wang Hongxia, Xu Xian, Wan Yiqun, Liu Yufeng, Wang Mingjie, Yu Wen, Dai Yongjing, Peng Jiang, Guo Quanyi, Yu Changlong, Lu Shibi
Institute of Orthopaedics, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China.
Trials. 2017 Nov 6;18(1):519. doi: 10.1186/s13063-017-2251-6.
Spontaneous recovery from articular cartilage injury is difficult, and the ongoing progression of disease can eventually lead to osteoarthritis. Currently, there is no effective non-surgical treatment for articular cartilage injury. Arthroscopic debridement and microfracture surgery are performed for fibrocartilage repair. But fibrocartilage is different from normal articular cartilage, and functional recovery is not satisfactory. Therefore, it is necessary to develop more effective techniques for articular cartilage repair. Progress in material science, cell biology, biomechanics, and bioreactor technology has allowed the development of biomimetic, tissue-engineered osteochondral composites that have shown potential for the repair of damaged cartilage. We prepared biomimetic, tissue-engineered cartilage scaffolds optimized for biochemical composition and structural characteristics. Based on the experience of our pre-clinical studies on animals, a human articular cartilage acellular matrix scaffold was prepared and is in clinical use. The combination of autologous chondrocytes and scaffolds has shown satisfactory results in repairing cartilage defects in preliminary experiments.
This is a prospective randomized controlled trial. One hundred patients with full-thickness cartilage injury of the knee will be randomly divided into two groups to receive treatment with either tissue-engineered cartilage constructed using biomimetic cartilage extracellular-matrix-oriented scaffolds combined with autologous chondrocytes, or arthroscopic debridement and microfracture surgery. There will be five visiting time points: at baseline, then at 3, 6, 12, and 18 months postoperatively. The primary outcome will be therapeutic efficacy as assessed by the Lysholm score at 12 months postoperatively. The secondary outcomes will be the International Knee Documentation Committee score, Visual Analog Scale score, and cartilage injury and repair as assessed by magnetic resonance imaging as well as the incidence of postoperative adverse events.
This trial will attempt to verify the use of tissue-engineered cartilage constructed using autologous chondrocytes combined with allogeneic, acellular cartilage matrix for the repair of cartilage defects, thereby providing favorable evidence for its use in clinical practice.
ClinicalTrials.gov, identifier: NCT02770209 . Registered on 11 May 2016.
关节软骨损伤自发修复困难,疾病持续进展最终可导致骨关节炎。目前,对于关节软骨损伤尚无有效的非手术治疗方法。关节镜下清创和微骨折手术用于纤维软骨修复。但纤维软骨与正常关节软骨不同,功能恢复并不理想。因此,有必要研发更有效的关节软骨修复技术。材料科学、细胞生物学、生物力学和生物反应器技术的进展使得仿生组织工程化骨软骨复合材料得以发展,其已显示出修复受损软骨的潜力。我们制备了针对生化组成和结构特征进行优化的仿生组织工程软骨支架。基于我们在动物身上的临床前研究经验,制备了一种人关节软骨脱细胞基质支架并已应用于临床。自体软骨细胞与支架的组合在初步实验中已显示出修复软骨缺损的满意效果。
这是一项前瞻性随机对照试验。100例膝关节全层软骨损伤患者将被随机分为两组:一组接受使用仿生软骨细胞外基质导向支架联合自体软骨细胞构建的组织工程软骨治疗,另一组接受关节镜下清创和微骨折手术。将有5个访视点:基线时,以及术后3、6、12和18个月。主要结局将是术后12个月通过Lysholm评分评估的治疗效果。次要结局将是国际膝关节文献委员会评分、视觉模拟量表评分、通过磁共振成像评估的软骨损伤和修复情况以及术后不良事件的发生率。
本试验将试图验证使用自体软骨细胞联合异体脱细胞软骨基质构建的组织工程软骨修复软骨缺损的效果,从而为其临床应用提供有力证据。
ClinicalTrials.gov,标识符:NCT02770209。于2016年5月11日注册。